3UK Prospective Diabetes Study(UKPDS)group.Intensive blood-glucose sulphonylureas or insulin compared with conventional treatment and risk of eomplicatious in patients with type 2 diabetes(UKPDS33).Lancet,1998,352:837-853.
4Stmtton IM,Adler A1,Neil HA,et al.Association of glyvaemia with macrovaseular and mierovascular complications of type 2 diabetes (UKPDS 35):prospective observational study.BMJ,2000,321:405-412.
5Gaede P,Vedei P,Larsen N,et al.Multifactorial intervention and cardiovacular disease in patients with 2 diabetes,N Engl J Med,2003,348:383-393.
6Guillausseau PJ.Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus:a focus on frequency of administration.Treat Endoerino1,2005,4:167 -i 75.
7Guillausseau PJ.Compliance and optimisation of oral antidiabetic therapy.A longitudinal study.Presse Meal,2004,33:156-160.
8Drouin P,Standl E for the diamieron MR study group.Gliclazide modified release:results of a 2-year study in patients with type 2 diabetes.Diabetes Obes Metab,2004,6:414-421.
9Jacek S,Teresa KC,Wladystaw G,et al.Applieatiou of gliclazide MR in uncontrolled diabetes type 2-the treatment phase results of DINAMIC 2 study.Diabetologia Praktyezna,2003,2:133-136.
10The ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med,2008,358:2560-2572.
